Koki Nakanishi, Chie Tanaka, Mitsuro Kanda, Kazushi Miyata, Nozomu Machida, Mitsuru Sakai, Daisuke Kobayashi, Hitoshi Teramoto, Akiharu Ishiyama, Bin Sato, Takashi Oshima, Masaki Kajikawa, Hidenobu Matsushita, Kiyoshi Ishigure, Katsuya Yamashita, Shinichi Fujitake, Satoshi Sueoka, Takahiro Asada, Dai Shimizu, Shizuki Sugita, Yachiyo Kuwatsuka, Osamu Maeda, Satoshi Furune, Kenta Murotani, Yuichi Ando, Tomoki Ebata, Yasuhiro Kodera
In Japan, systemic chemotherapy is the standard treatment for unresectable, advanced, or recurrent gastric cancer. However, numerous patients with gastric cancer do not receive late-line treatment because of the rapid progression of gastric cancer. Additionally, late-line treatments, such as nivolumab, trifluridine tipiracil (FTD/TPI), or irinotecan, have limited effects on improving clinical symptoms and delaying the onset of symptoms associated with cancer progression. Recently, a combination of FTD/TPI and ramucirumab was reported to have a high response rate in late-line treatment; however, owing to patient selection bias and a high rate of hematologic toxicity in that previous study, this regimen may not be feasible in real-world clinical applications...
February 2024: Nagoya Journal of Medical Science